药易购(300937.SZ):拟新设全资子公司 实施药易购跨境医贸总部项目
格隆汇6月26日丨药易购(300937.SZ)公布,为积极探索开展跨境电商零售进口药品模式,打造药易购跨境医贸总部、构建数智医药大健康产业链新生态,公司及全资子公司海南药易购生物科技有限公司(曾用名:海南美迪康生物科技有限公司,简称“海南药易购”)拟与成都国际铁路港经济技术开发区管理委员会签署《项目投资协议》,公司拟以货币出资的方式投资人民币2000万元,由海南药易购在成都市青白江区新设一家全资子公司成都药易购供应链有限责任公司(暂定名,具体名称以工商登记为准)作为推进主体实施药易购跨境医贸总部项目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.